DHR
$232.00-0.42%
as of close, Oct 27, 2026
☾ AH $232.00 -0.42%
DHR — Danaher Corporation price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDE
80.0100.0120.0140.0160.0180.0200.0220.0240.0260.0280.00200.0M$232.00—20162019202120242026
2026-10-27
Price$232.00
MA20$203.17
MA50$206.37
Vol16.6M
Key stats#
Price data
- Price
- $232.00
- YTD price return
- +1.35%
- YTD total return
- +1.95%
- Market cap
- 163.2B
- Enterprise value
- 185.3B
- Shares outstanding
- 703.5M
- 52W low
- $160.93
- 52W high
- $242.80
- From 52W high
- -4.45%
- From 52W low
- +44.16%
- 52W range
- 87%
- Beta
- 0.77
Volume
- Rel volume
- 0.51×
- 30D volume
- 4.9M
- 30D $ vol
- 1.1B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$12.7M
- Insider net 1Y
- −$13.2M
Form 4 transactions by trade date, as filed; latest on file 2026-08-21.
Fundamentals
- Sales (ttm)
- 25.6B
- Sales/share
- $36.40
- EPS (ttm)
- $6.11
- FCF (ttm)
- 5.7B
- FCF/share
- $8.14
- Book value/share
- $76.22
- Net margin
- 16.91%
- ROE
- 8.08%
- ROA
- 4.64%
- Debt / equity
- 0.45×
- Current ratio
- 1.63
Growth (CAGR, ttm) · 10Y
- Sales
- +5.54%+1.33%-1.82%+4.42%
- Net income
- +23.73%-9.91%-5.97%+5.68%
- FCF
- +14.20%-5.78%-4.10%+4.99%
- Shares
- -0.40%-1.63%-0.31%+0.17%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +25.73%-8.36%-5.40%+5.50%
- Sales/share
- +5.97%+3.00%-1.51%+4.25%
- FCF/share
- +14.66%-4.22%-3.80%+4.81%
- Book value/share
- +5.43%+2.44%+4.64%+8.57%
- Dividend/share
- +20.51%+9.03%+7.46%+9.44%
- Price
- +4.98%+7.28%-3.03%+12.90%
- Total return
- +5.75%+7.91%-2.54%+13.48%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 38.0×
- P/OI (ttm)
- 31.3×
- Fwd P/E
- 24.7×
- P/S (ttm)
- 6.4×
- P/B (mrq)
- 3.0×
- P/FCF (ttm)
- 28.5×
- EV/EBITDA (fy)
- 23.6×
- EV/Sales (ttm)
- 7.2×
- FCF yield (ttm)
- 3.51%
- Dividend yield (fwd)
- 0.69%
- Dividend yield (ttm)
- 0.66%
- Dividend/share (fwd)
- $1.60
- Buyback yield (realized, 1y)
- 0.40%
- Shareholder yield (realized, 1y)
- 1.18%
- Buyback yield (cash, ttm)
- 0.55%
- Shareholder yield (cash, ttm)
- 1.17%
Vs own 10Y history
- P/E
- 75th
- P/OI
- 74th
- P/S
- 57th
- P/B
- 51st
- P/FCF
- 71st
Bar = where today’s multiple sits in DHR’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
-0.42%
5D
+3.46%
1M
+3.35%
3M
+18.07%
YTD
+1.35%
1Y
+4.97%
5Y
-14.27%
Recent filings#
- Oct 21Earnings · Earnings release — EPS $2.11 vs $1.92 est. (+9.9%); revenue $6.55B (+8% y/y)
- Aug 21Insider sale · Blair Rainer (President & CEO · Director) sold 58,255 shares for $12.7M at $217.77–$219.35
- Aug 38-K · Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer
- Jul 21Earnings · Earnings release — EPS $1.94 vs $1.84 est. (+5.4%); revenue $6.26B (+6% y/y) 11.0%
Financial statements
Open full DHR financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
